Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.
The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
University Hospital of Crete, Heraklion, Crete, Greece
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
Department of Medical Oncology, "Marika Iliadis" Hospital of Athens, Athens, Greece
Good Samaritan Hospital, Dayton, Ohio, United States
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
University Hospital of Crete, Dep of Medical Oncology, Heraklion, Crete, Greece
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
University Hospital of Crete, Dep of Medical Oncology, Heraklion, Crete, Greece
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
Maine Center For Cancer Medicine, Scarborough, Maine, United States
Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States
Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
University Hospital of Heraklion, Heraklion, Crete, Greece
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
UT Southwester Med Ctr at Dallas, Dallas, Texas, United States
Texas Cancer Center - Denton, Denton, Texas, United States
Longview Cancer Center, Longview, Texas, United States
Krankenhaus Nordwest, Frankfurt, Germany
Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.